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Background: Aristolochic Acid (AA), a natural component of Aristolochia plants that is found in a variety of herbal
remedies and health supplements, is classified as a Group 1 carcinogen by the International Agency for Research
on Cancer. Given that microRNAs (miRNAs) are involved in cancer initiation and progression and their role remains
unknown in AA-induced carcinogenesis, we examined genome-wide AA-induced dysregulation of miRNAs as well
as the regulation of miRNAs on their target gene expression in rat kidney.
Results: We treated rats with 10 mg/kg AA and vehicle control for 12 weeks and eight kidney samples (4 for the
treatment and 4 for the control) were used for examining miRNA and mRNA expression by deep sequencing, and
protein expression by proteomics. AA treatment resulted in significant differential expression of miRNAs, mRNAs
and proteins as measured by both principal component analysis (PCA) and hierarchical clustering analysis (HCA).
Specially, 63 miRNAs (adjusted p value < 0.05 and fold change > 1.5), 6,794 mRNAs (adjusted p value < 0.05 and fold
change > 2.0), and 800 proteins (fold change > 2.0) were significantly altered by AA treatment. The expression of 6
selected miRNAs was validated by quantitative real-time PCR analysis. Ingenuity Pathways Analysis (IPA) showed that
cancer is the top network and disease associated with those dysregulated miRNAs. To further investigate the
influence of miRNAs on kidney mRNA and protein expression, we combined proteomic and transcriptomic data in
conjunction with miRNA target selection as confirmed and reported in miRTarBase. In addition to translational
repression and transcriptional destabilization, we also found that miRNAs and their target genes were expressed in
the same direction at levels of transcription (169) or translation (227). Furthermore, we identified that up-regulation
of 13 oncogenic miRNAs was associated with translational activation of 45 out of 54 cancer-related targets.
Conclusions: Our findings suggest that dysregulated miRNA expression plays an important role in AA-induced
carcinogenesis in rat kidney, and that the integrated approach of multiple profiling provides a new insight into a
post-transcriptional regulation of miRNAs on their target repression and activation in a genome-wide scale.
Keywords: Aristolochic acid, Carcinogenesis, Kidney tumor, microRNA, Proteomics, Deep-Sequencing, RNA array,
Target prediction, Rat* Correspondence: tao.chen@fda.hhs.gov
†Equal contributors
2Division of Genetic and Molecular Toxicology, National Center for
Toxicological Research, Food and Drug Administration, 3900 NCTR Road,
Jefferson, AR 72079, USA
Full list of author information is available at the end of the article
© 2015 Li et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. BMC Genomics  (2015) 16:365 Page 2 of 11Background
Aristolochic acid (AA) is found in plants of the genus
Aristolochia and Asarum [1]. Use of dietary supplements
and other botanical products containing AA has caused
severe nephrotoxicity and consequent renal replacement
therapy [2,3]. Animal studies show that AA results in
renal failure in rodents and induces tumors in the kidney
and other tissues of rabbits, rats and mice [4,5]. AA is
among the most potent 2% of the carcinogens in the
Carcinogenic Potency and Genotoxicity Databases. As a
result, the U.S. Food and Drug Administration (FDA)
issued a Consumer Advisory in 2001 warning consumers
against using dietary supplements and other botanical
products containing AA, and the FDA also requested a
recall of these products and published a list of botanical
products that contained AA. However, products contain-
ing AA have not been banned in the US or many other
countries. AA-induced carcinogenesis has been attrib-
uted to the mutagenicity and DNA adducts formed in
the kidney and other tissues of AA nephropathy pa-
tients. On the other hand, AA induced similar DNA ad-
duct formation in both the kidney and liver of mice, but
tumors preferentially occurred in kidney [6]. This sug-
gests that in addition to the genetic alterations induced
by AA, alternative mechanisms such as epigenetic re-
modeling and miRNA (miRNA) modulation might also
play an important role in AA-induced cancers.
miRNAs represent a class of non-coding small RNA
(~22 nt) that are ubiquitously present in different kinds
of organisms from C.elegans to mammals [7,8]. miRNAs
are involved in the post-transcriptional regulation of
gene expression via binding to the 3’ UTR region of tar-
get mRNAs, resulting in mRNA degradation or transla-
tion inhibition [8]. Each miRNA usually targets multiple,
even hundreds of mRNAs [9]. It is believed that one
third of human genes are subject to miRNA control.
miRNAs regulate a variety of developmental and physio-
logical processes, including control of leaf and flower de-
velopment in plants [10] and neuronal patterning in
nematodes [11]. Recent studies indicate that miRNAs
are involved in the regulation of pathways that are asso-
ciated with the initiation and progression of many types
of tumors [12-14]. miRNA expression was found to ac-
curately identify the tissue origin of cancers, including
distal metastatic colonies of unknown primary origin
[15]. miRNAs affect tumor metastasis, such as the lung
and bone metastasis of human breast cancer [16]. More-
over, miRNAs are associated with chemical carcinogen-
esis and regulate gene expression that is important in
every stage [17].
Deep sequencing, also known as next generation se-
quencing, has undergone tremendous acceptance in the
past few years. By sequencing DNA or RNA in a mas-
sively parallel fashion, deep sequencing technologiesdramatically reduce both the cost-per-base and time re-
quired to decode an entire genome or transcriptome
[18-20], making sequencing a cost-effective option for
many experimental approaches. Moreover, it has very
low, if any, background signal, and does not have an
upper limit for quantification, resulting in a large dy-
namic range of expression levels over which transcripts
can be detected [21]. Toxicoproteomics is a new discip-
line that applies proteomics concepts and approaches to
toxicological studies. It can elucidate pathological re-
sponses to a specific toxicant at the protein molecule
level, including qualitative and quantitative measure-
ments of protein expression, protein modifications, and
protein-protein/toxicant interactions [22].
A primary research objective of miRNA biology is to
understand the post-transcriptional regulation of the
target genes and the effect on biological functions.
However, due to the different mechanisms of miRNA
regulation, the targets can be translationally repressed
with a concordant decrease in mRNA abundance or
without significant mRNA degradation, or have de-
creased mRNA abundance with little protein change
[23-25]. Moreover, miRNAs can switch from repression
to activation depending on different stages of the cell
cycle [26]. Therefore, in order to understand miRNA
regulation in AA-induced kidney tumorigenesis, we inte-
grated deep sequencing data for global miRNA and
mRNA expression with proteomics data for global pro-
tein expression in conjunction with target identification
of dysregulated miRNAs from the miRTarBase [27,28].
Compared with using miRNA target prediction tools
such as miRanda and TargetScan [29,30], we selected
those targets that were published and validated to study
their miRNA transcriptional and translational regula-
tions [31,32], thus providing a novel approach to en-
hance our understanding of the biological role of
miRNA in AA-induced carcinogenesis in rat kidney. The
details of the proteomics data from rats treated with AA
were reported separately [33]. This work will contribute
to our understanding of the biological processes driving
AA-induced carcinogenesis at the miRNA, mRNA and
protein levels as well as representing a generalizable
strategy that can be extended to study the functional
role of miRNAs and their regulation of target expression
in organs or tissues of interest.
Results
AA treatment resulted in functionally differential miRNA
expressions in rat kidney
Dysregulated miRNA expression has been linked to can-
cer in experimental animal models and patients [34]. To
investigate the effects of AA exposure on miRNA ex-
pression under conditions that resulted in kidney tu-
mors, we treated 4 rats for 12 weeks with AA along with
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netic protocol that has been demonstrated to result in
kidney tumors [35]. All the rats were sacrificed one day
after the last treatment and the kidneys were removed
for miRNA deep sequencing analysis. The short reads
were mapped to Sanger miRBase (miR 16) [36]. There
were 417 detectable miRNAs in at least one of the 8
samples. First, classification analyses were conducted to
explore global alteration of miRNAs by the AA treat-
ment. Hierarchical clustering analysis (HCA) was per-
formed to globally view the groups among the 8 samples
in terms of the expression profile of all the detectable
miRNAs. These samples are divided into two branches,
one comprises 4 AA-treated samples and the other con-
tains the 4 control samples. This indicates that miRNAs
have similar and consistent expression patterns within
each group, but are distinct from each other, demon-
strating the profound impact of AA treatment on
miRNA expression in rat kidney (Figure 1A). The same
phenomenon was revealed by the principal component
analysis (PCA) analysis, further supporting that miRNA
expression is profoundly changed by AA treatment at
the genome scale.
Next, we investigated which miRNAs were significantly
dysregulated by AA treatments. All the 417 detectable
miRNAs were used to find differentially expressed miRNAsFigure 1 Identification of differentially expressed miRNA and mRNA in kidn
expression intensity of the 417 detectable miRNAs. Hierarchical clustering a
with control and the treatment groups. Principal component analysis grou
8 samples according to expression level of the 23939 detectable mRNAs. Hier
are consistent with the control and treatment groups. Principal component a(DEM). Read count normalization, statistical analysis and p
value adjustment were performed using the DEseq
methods. Sixty-three miRNAs showed significant changes
in their expression level by AA treatment using a cutoff
with adjusted p values of < 0.05 and fold change of > 1.5
(Additional file 1: Table S1). More up-regulated miRNAs
(n = 43) were observed than down-regulated miRNAs (n =
20).rno-miR-881, rno-miR-880, miR-741-3p, miR-511*,
miR-187, miR-449a, as well as 6 members of miR-34 fam-
ily, miR-34a, miR-34a*, miR-34b, miR-34b*, miR-34c, and
miR-34c*, showed over 10-fold up-regulation. In contrast,
only one miRNA, miR-383, showed more than 10-fold
down-regulation. Moreover, the oncogenic miRNA, mir-21
was increased 3.8 fold, whereas the tumor suppressor miR-
NAs, Let-7e, mir-135a, and mir-375 were decreased by 2.9,
2.7 and 5.9 fold, respectively. In order to validate the
changes in miRNA expression detected by a deep-
sequencing, we conducted quantitative real-time PCR ana-
lysis to examine expression levels of six miRNAs including
rno-miR-378, rno-miR-182, rno-miR-21, rno-miR-34a,
rno-miR-34b, and rno-miR34c. The results from the
real-time PCR analysis confirmed the sequencing data
(Additional file 2: Figure S1).
Finally, 63 miRNA target proteins that were dysregu-
lated in rat kidney were inputted into the Ingenuity data-
base to explore the underlying biological and toxicologicaley in rat treated with AA. A. Classification of samples according to
nalysis separates the 8 samples into two groups that are consistent
ps samples into the AA- treated and control clusters. B. Classification of
archical clustering analysis separates the 8 samples into two groups that
nalysis groups samples into the AA- treated and control clusters.
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cancer was the top functional category significantly related
to these miRNAs, along with organismal injury and abnor-
malities, which also could result from AA treatment. In
total, 31 of the 63 miRNAs were cancer-related (Table 1).
Differentially expressed genes (DEGs) from mRNA
sequencing data and their functions
miRNAs regulate the homeostatic level of their target
mRNAs. To investigate whether mRNA expression was
also changed by AA treatments, the 8 rat kidney samples
were analyzed by mRNA deep sequencing analysis in par-
allel. The short reads were mapped to Ensembl transcripts
(RGSC3.4), and a data processing procedure similar to
that used for the miRNAs was applied to normalize the
raw counts, and to calculate adjusted p values. There were
23939 mRNAs that had detectable expression in these 8
samples. As with miRNA expression in rat kidney, the ex-
pression patterns of mRNA were similar within the treat-
ment or control group alone, but distinctly between the
two groups in both HCA and PCA analysis (Figure 1B). A
total of 6794 richness mRNAs were found to be differen-
tially expressed based on a cutoff of p < 0.05 and fold
change > 2, with 4051upregulated and 2743 down-
regulated. Ingenuity Pathway analysis (IPA) of both up-
regulated and down-regulated genes identified cancer as
the top disease and biological function with 1197 up-
regulated and 685 down-regulated molecules included
(p = 1.48-22E-1.09E-06 and p = 4.95-14E-1.64-02E, re-
spectively). The top canonical pathways included
WNT/β-actin, mitochondrial dysfunction and valine
degradation. (Additional file 3: Figure S2).
An integrated multiple profiling reveals a comprehensive
regulation of miRNAs on their target expression
In order to search for the targets of its differentiately
regulated miRNAs and understand effects of the post-
transcriptional regulation of miRNA on gene expression
in AA-induced carcinogenesis, we combined proteomic
and transcriptomic data to study expression of theTable 1 IPA analysis of 63 dysregulated miRNAs in rat
kidney treated with AA
Top networks (score) Top diseases and functions
Cancer, Organismal Injury and
Abnormalities (30)
Cancer
Cancer, Endocrine System
Disorders (25)
Organismal Injury and
Abnormalities
Cancer, Hematological Disease,
Immunological Disease (21)
Reproductive System Disease
Drug Metabolism, Lipid Metabolism,
Molecular Transport (8)
Endocrine System Disorders
Gastrointestinal DiseasemiRNA targets that are validated and reported in miR-
TarBase (http://mirtarbase.mbc.nctu.edu.tw/). This data-
base provides the most current and comprehensive
information on experimentally validated miRNA-target
interactions and data resources with published studies
on the identification of miRNA targets, molecular net-
works of miRNA targets and systems biology. Specific-
ally, it contains 5224 miRNA targets that are validated
by one or more solid experimental methods including
luciferase reporter assay, western blot, northern blot,
and quantitative real-time analysis. If a gene is targeted
by multiple miRNAs, the log2 transformed fold changes
of these miRNAs were summed together as the fold
changes of the miRNAs.
We initially conducted correlation analysis between
the miRNAs vs. mRNAs, miRNAs vs. proteins, and
mRNAs vs. proteins in rat kidney treated with AA in re-
lation to the control. There was a very weak correlation
between expression of mRNAs versus proteins (R = 0.02,
P < 0.001), and miRNAs vs. proteins (R = 0.003, P <0.01),
but there was no correlation between miRNA vs. mRNA
expression (R = 0.002, P =0.85) (Additional file 4: Figure
S3), indicating that regulation by miRNAs on their target
genes can be attributed to multiple mechanisms.
Next, we divided our study into two groups including
group A, the up-regulated miRNAs and group B, the
down-regulated miRNAs, and used an adjusted p < 0.05
and fold changes of < -1.5 or > 1.5 as a cutoff, indicating
the difference for all these three variables. According to
the response of gene expression in group A, we sepa-
rated our study into three subgroups: 1) mRNAs and
proteins expressed in the same direction including up-
regulated (68), down-regulated (39), not changed (191). 2)
mRNAs and proteins expressed in the opposite direction
including 35 down-regulated mRNAs vs. up-regulated
proteins and 17 up-regulated mRNAs vs. down-
regulated proteins, and 3) miRNA targeted gene trans-
lation indicated by protein up-regulated (74) or down-
regulated (37) without a change in mRNA expression,
or targeted transcription indicated by mRNA up-
regulated (53) or down-regulated (104) without a
change in protein expression (Figure 2A).
Similarly, for group B, we separated our study into
three subgroups: 1) mRNAs and proteins expressed in
the same direction including both up-regulated (13),
down-regulated (20), and not changed (14); 2) mRNAs
and proteins expressed in the opposite direction including
13 down-regulated mRNAs vs. up-regulated proteins and
11 up-regulated mRNAs vs down-regulated proteins, and
3) miRNA targeted translation indicated by protein up-
regulated (40) or down-regulated (23) without a change in
mRNA expression, or targeted transcription indicated by
mRNA up-regulated (28) or down-regulated (17) without
a change in protein expression (Figure 2B).
Figure 2 miRNAs regulated their target gene expression. A. genome-wide mRNA and protein expression associated with down-regulated miRNAs
in rat kidney. We identified 63 dysregulated miRNAs and selected their targets that are validated and reported from miRTarBase and correlated
with their mRNA and protein expression. B. Genome-wide mRNA and protein expression associated with up-regulated miRNAs in rat kidney.
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lation on their target expression, indicated by both re-
pression and activation at levels of transcription and
translation. Also, miRNAs affected gene translation
without a change in mRNA abundance and vice versa.
The correlation of expression between mRNAs and pro-
teins was very weak, indicating that post-transcriptional
regulation by miRNAs or other factors are involved in
this regulation.miRNA-target interaction networks associated with cancer
in rat kidney treated with AA
We examined the interactions of miRNA with cancer
specific targets that were expressed at the protein level
and more related to their functional regulation. We used
IPA analysis to pull out all the cancer-related miRNAs'
targets from miRarBase and matched with 31 dysregu-
lated miRNAs associated with cancer in rat kidney
treated with AA. Therefore, we created miRNA regula-
tion networks that link miRNAs and their targets to
AA-induced carcinogenesis in rat kidney. For example,
we identified 12 cancer-related targets associated with
down-regulated miRNAs. Among these, 9 targets were
down-regulated for protein expression and only 3 were
up-regulated (Figure 3A). Also, 54 cancer related targets
were associated with 13 up-regulated oncogenic miR-
NAs. Among these, 45 targets were up-regulated for
protein expression, and only 9 were down-regulated
(Figure 3B). In other words, miRNAs exhibited a bi-
directional regulation of their targets and most cancerrelated target expression had the same direction as the
miRNA expression, an unexpected finding.
We next selected several few specific oncogenic miRNAs
and examined their targets' expression. For example, miR-
21 was up-regulated in rat kidney. The expression of its
target genes Ppp3cb and Kras were down-regulated, but
eight target genes including YWHAH, TXNRD2, LDHA,
ACE, EIF5B, SPARC, ITPRC, AND PCNA were up-
regulated, and these targeted genes are related with several
cancer signaling pathways including ERK/MAPK, PI3K/
AKT, and 14-3-3 mediated signaling. miR-34a was up-
regulated. The expression of its target genes LCAM1 AND
AMACR were down-regulated, but 7 out of 9 miR-34a's
targets were up-regulated including TUBBS, LDHA,
NAMPT, ENO3, GGH, TXNRD2, and LMNA which are
associated with mitochondrial dysfunction, DNA damage
and repair, and apoptosis (Figure 3C).
Discussion
The International Agency for Research on Cancer
(IARC) has classified herbal remedies containing plant
species of the genus Aristolochia as human carcinogens
(IARC, 2002). In the present study, we profiled the ex-
pression of miRNA, mRNA and protein in the kidney of
rats treated with a carcinogenetic dose of AA. We also
employed an integrative methodology to study the corre-
lations among miRNA, mRNA, and protein expression
during AA-induced kidney carcinogenesis. We found
that miRNA expression was significantly changed by AA
treatment, with 63 altered miRNAs, accounting for 15%
of 417 detectable miRNAs. We performed real-time
miRNA-targets in the opposite direction
miRNA-targets in the same direction
A
C
B
Figure 3 Interaction of miRNAs with their cancer-related protein targets. (A) miRNA targets were selected from IPA analysis and matched to
miRNAs that were down-regulation. (B) miRNA targets matched to miRNAs that were up-regulated. miRNA targets – protein expression that has
the same direction indicated by the red color and opposite direction indicated by the green color. (C) Highlighted miRNA-target interactions of
miR-21, miR-34a, miR-122, and miR-135a.
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by deep-sequencing analysis. Moreover, in a genome-
wide analysis, we found that altered miRNA expression
had different effects on their target at the levels of both
transcription and translation. We further determined
that miRNA regulation is associated with both gene re-
pression and activation, which could help us better
understand miRNA biology in AA-induced rat kidney
tumorigenesis.
miRNA dysregulation is recognized as a driving force
in human cancer. Alteration of miRNA expression is
commonly observed following exposure to different car-
cinogens [17,37,38], but the role of miRNAs in AA-
induced carcinogenesis was not studied previously.Genetic changes are frequently observed in experimental
animal models treated with AA. For example, we have
previously shown that AA induces a high frequency of
DNA mutations, with A:T→ T:A transversion as the
predominant mutation type [6]. In addition to the gen-
etic changes induced by AA, we have found that AA
treatment result in dysregulation of miRNAs and that
half of them are associated with cancer according to IPA
analysis. We selected up-regulation of oncogenic miR-
NAs such as mir-21 as well as down-regulation of
the tumor suppressor miRNAs Let-7e, mir-135a, and
mir-375 for our analysis. In patients, miR-135a inhibits
cancer cell proliferation and exhibits the properties of a
tumor suppressor in renal-cell carcinoma [39], while its
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determined by proteomics. A recent study demonstrates
that AA treatment altered a number of miRNAs in prox-
imal tubular epithelial cells such as up-regulation of
miR-192, miR-194, miR-450a, and miR-542. miR-192
mediated DNA damage response and recapitulated G2/
M arrest via repression of murine double-minute 2, a
negative regulator of P53 [40]. Similarly, we found that
AA treatment increased expression of miR-450a and
miR-542, and that AA induced a DNA damage response
indicated by up-regulation of miR-34a. It was followed
by activation of P53 and the binding P53 to the pro-
moter of miR-34a resulted in mir-34 activation [41]. On
the other hand, we did not see any consistency of 9
down-regulated miRNAs as identified in that study. This
discrepancy could be explained by the fact that we used
an in vivo model to study AA-induced carcinogenesis,
which might be affected by many factors such as micro-
environment, immune factors, and so on. All of these
are not modeled in an in vitro study. It is likely that the
carcinogenic effects of AA depend upon the balance be-
tween the oncogenic miRNAs and tumor-suppressor
miRNAs. Thus, the alterations in these miRNAs might
play an important role in promoting tumor development
in rat kidney as well as inducing kidney toxicity, suggest-
ing that identifying the miRNA targets involved in these
processes are important.
We combined multiple levels of profiling to study
miRNA target expression and identified those targets of
dysregulated miRNAs that are validated and reported
from miRTarBase. Currently, miRNA target identifica-
tion is primarily based on computational predications
that could result in a vast number of targets with errors,
raising the problem of identifying functional targets for
validation [42]. From our knowledge, this is the first
time that this novel approach has been used to study the
relationship among three levels of expression of miRNA,
mRNA and protein on a genome-wide scale. Even though
there might be some missing targets for miRNAs identified
in this study in the miRTarBase, we have identified several
categories of miRNA-target relationship that might repre-
sent general miRNA regulation patterns and the biological
operating during AA-induced carcinogenesis.
In general, there are two possible post-transcriptional
mechanisms accounting for miRNA regulation of its tar-
get genes, mRNA cleavage or translational repression,
both of which negatively regulate target expression. If an
mRNA target is perfectly or near-perfectly complementary
to the miRNA, the mRNA will be cleaved and degraded.
mRNA translation also can be repressed. Consequently, we
identified a number of miRNA targets that show transla-
tional repression or mRNA destabilization or both. On the
other hand, a number of miRNA targets identified in this
study pair with proteins show expression in oppositedirection to the change in miRNA expression, but the
mRNA level remains unchanged. This is consistent with
previous reports that most animal miRNAs complement
their targets imperfectly so they function primarily via
translational repression rather than mRNA cleavage and
degradation [17].
However, we identified a number of miRNA targets
with expression of miRNAs and proteins in the same
direction. Moreover, we have discovered a network of
miRNAs and their functional target interactions associ-
ated with AA-induced tumors that show both directions
of miRNA - target regulation and most of them are actu-
ally expressed in the same direction. In certain cases
miRNAs and their potential targets were observed to have
similar expression patterns [43-45]. Such a phenomenon
might be explained by counter-regulation of different post-
transcriptional mechanisms or possibly the down-
regulation of protein production being offset by a feedback
mechanism [23]. In this study, it remains intriguing that
up-regulation of miRNAs such as miR-21 and miR-34a
is associated with activation of their target oncoprotein
expression after AA treatment for 12 weeks. It remains un-
known how miRNAs could maintain the target overexpres-
sion that could be a driving force for AA-induced
carcinogenesis. So far, miRNA biology studies mainly have
focused on miRNA targets with an opposite regulation or a
similar expression with the anti-targets. Our research is
based on a genome-wide approach and highlights the im-
portance of considering both sides of miRNA regulation,
including translational repression resulting in activation in
biological functions and diseases.
Finally, we found that there was only a weak correl-
ation between mRNA and protein expression or even
opposite expression for a number of genes. One possibil-
ity for this lack of association is the different stability of
proteins in the rat [46,47]. For example, the half-life of
different proteins varies from minutes to days, but the
variability for mRNAs is quite a bit less. Also, post-
transcriptional and post-translational regulation might
affect protein expression. miRNAs are also likely in-
volved in this process and might regulate gene expres-
sion through feedback mechanisms, but the mechanisms
for these pathways are largely unknown. However, we do
not preclude the possibility that mechanisms may be im-
portant including transcriptional factors, translational or
posttranslational regulation that would affect miRNA
target expression.
In summary, we treated rats with a carcinogenic dose
of AA and identified dysregulated expression of 63 miR-
NAs in rat kidney by performing a deep sequencing ana-
lysis. IPA analysis indicated that half of them are
associated with cancer. We next selected miRNA targets
based on those dysregulated miRNAs and combined
miRNA data with the RNA microarray and proteomics
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gets regulation. The ability to compare miRNA, mRNA,
and protein expression in the identical samples defined a
comprehensive miRNA regulatory network that indicated
RNA destabilization, translational repression and activation.
Conclusions
We employed global profiling of miRNA, transcriptome,
and proteome expression in parallel in order to integrate
three biological system levels to better understand AA-
induced carcinogenesis in rat kidney. AA induced a
number of dysregulated miRNAs that are closely associ-
ated with cancer initiation and progression. Moreover,
the use of integrated approaches helps us better under-
stand the relationships among expression of miRNAs,
mRNAs and proteins with a focus on miRNA regulation
on genome-wide repression and activation. We identi-
fied a cancer-related network that is associated with
miRNA target regulation, primarily regulating transla-
tional activation. This novel systematic study provides us
information on miRNA target regulation on a genome-
wide scale. The study supports application of miRNA ex-
pression as a biomarker for identifying the genotoxicity
and carcinogenicity of AA and other of unknown
exposures.
Methods
Animal treatment
The treatment schedule was based on the previous car-
cinogenicity study of AA that resulted in tumors in kid-
neys and other tissues [27,28]. Specifically, groups of six
6 week-old male Big Blue rats were treated with AA as
its sodium salt at 10.0 mg/kg body weight by gavage
(4 ml/kg body weight) 5 times a week for 12 weeks, a
treatment protocol that induces tumors in rat kidney.
Rats treated with 0.9% sodium chloride on the same
schedule were used as control. All animals were sacrificed
1 day after the last treatment. The kidneys were isolated,
frozen quickly in liquid nitrogen and stored at −80°C.
The rats were obtained from Taconic Laboratories
(Germantown, NY) and were originally purchased from
Stratagene (La Jolla, CA). AA was purchased from
Sigma (St. Louis, MO). The purity of AA was 96% and
contained 40% of AAI and 56% of AAII. The recom-
mendations set forth by the NCTR Institutional Animal
Care and Use Committee were followed for the hand-
ling, maintenance, treatment and sacrifice of the rats.
miRNA isolation
miRNA isolation was performed as previously described
[29]. Briefly, 40–50 mg tissue was cut and mechanically
minced using Tissue Tearor (Biospec Products Inc, OK).
Total RNA was isolated using a small RNA-retaining
protocol that employed an organic extraction followedby glass-fiber immobilization (Ambion, TX). RNA con-
centration was determined with a Nanodrop ND-1000
spectrophotometer (Thermo Scientific, DE). We used
sample-specific chips from 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA) to study RNA quality. The
RNA integrity was expressed as RNA integrity number
(RIN). We used samples for RNA express array and deep
sequencing with high qualities that had a RIN > 8.0.
Sequencing analysis of miRNA expression
The small RNA library construction and deep sequen-
cing were carried out at the University of Texas South-
western Medical Center Microarray Core Facility.
Samples were prepared using the Illumina Small RNA
Sample Prep Kit and following the small RNA v1.5 sam-
ple preparation guide. Approximately 10 μg of total
RNA was used for small RNA library construction. The
v1.5 sRNA 3’ and SRA 5’ adaptors (Illumina, USA) were
added to both ends of the small RNA. The 3’ and 5’ li-
gated RNAs were used as templates for reverse tran-
scription followed by PCR amplification. The enriched
cDNA constructs were loaded onto to 6% TBE PAGE
gel and the bands containing the 22–30 nt RNA frag-
ments (93–100 nt in length with both adapters) were cut
and purified. The concentrations of the libraries were
determined using a NanoDrop ND-1000 spectropho-
tometer and the size and purity were determined using
an Agilent 2100 Bioanalyzer in combination with the
Agilent DNA 1000 Kit. The purified DNA was used dir-
ectly for cluster generation and sequence analysis using
the Illumina Genome Analyzer II (Illumina, San Diego,
CA, USA) according to the manufacturer’s instructions
(36 cycle single read cluster kit v4 and sequence kit v4).
The image files generated by the sequencer were then
processed to produce digital-quality data. After masking
of the adaptor sequences and removal of contaminated
reads, clean reads were processed for computational
analysis. The read numbers for the 4 AA-treated and 4
control animals reached 17.1, 17.1, 16.3, 22, and 16.5,
16.4, 16.7, 19.7 millions, which provided enough cover-
age depth for miRNA profiling analysis. The miRNA se-
quencing data was deposited into GEO database with
the access number GSE54338.
Sequencing analysis of mRNA expression
mRNA sequencing was done with an Illumina Genome
Analyzer II platform by following the corresponding
manufacture protocols. Briefly, poly-A mRNA was iso-
lated from total RNA with Sera-Mag Magnetic Oligo
(dT) beads, and fragmented into small pieces using diva-
lent cations under elevated temperature. RNA fragments
were then used to synthesize the first and second strand
cDNAs using reverse transcriptase and random primers.
The ends of cDNA were blunted in an “end repair”
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polymerase. An “A” base was then added to the 3’ end
of the blunt phosphorylated DNA fragments, which was
used to ligate to the Illumina adapter with a single “T”
base overhang at its 3’ end. After the ligation reaction, a
size range of cDNA templates was selected and amplified
on a cluster station with the single-read cluster generation
kit v2. Finally, cDNA template clusters were sequenced on
an Illumina Genome Analyzer II platform with SBS Se-
quencing Kit v3. Each RNA sample was sequenced in one
lane, generating over 16 million reads of 36 bases long per
sample. Base-calling was done by Bustard [48], and se-
quence analysis was performed with Gerald (http://support.
illumina.com/content/dam/illumina-support/documents/
myillumina/a557afc4-bf0e-4dad-9e59-9c740dd1e751/casa
va_userguide_15011196d.pdf). The mRNA sequencing
data was deposited into GEO database with the access
number GSE21210.
Mapping of miRNA and mRNA short sequencing reads
We used the miRanalyzer webserver [30] for detection
of known miRNAs (http://www.mirbase.org/). The re-
quired input in read/count format was generated by
means of the provided groupReads.pl perl script. For
both analysis steps, conversion of fastq to read/count
and analysis of the miRNA expression profiling, we used
the default parameters of the programs. To detect differ-
entially expressed genes, we proceeded as following: (i)
download all Ensembl transcripts in fasta format
(RGSC3.4); (ii) align the reads with Bowtie [31] using a
seed alignment of 18 nt and allowing 1 mismatch. Ini-
tially we retained the best 10 alignments (−−best
–strata) by performing a seed extension to find the best
alignment(s) as described in the miRanalyzer paper. Fi-
nally we accepted the alignments if equal or less than
the 9 best alignments (after the seed extension) existed.
(iii) We calculated the read count for each reference se-
quence (Ensembl transcript). Note that by doing so, a
read with multiple mappings will contribute to the total
read count of several transcripts. Another way would be
to distribute the read count equally over the multiple
mapped transcripts (dividing the read count of an am-
biguously mapped read by the number of mappings).
However, this would lead to non-integer read counts
which might cause inappropriate mismatches between
mRNAs and microRNAs in DESeq. Moreover, we are in-
terested in differentially expressed mRNA and therefore
the effect of the multiple mapping treatments will cancel
out between the two conditions.
Data normalization and selection of differentially expressed
miRNAs (DEMs) and differentially expressed genes (DEGs)
We used the DESeq bioconductor package to detect
differentially expressed miRNAs and mRNAs [31].miRanalyzer incorporates a differential expression
module based on DESeq. For the mRNA sequencing
data, we built an expression matrix with raw read
counts of all transcripts and conditions that are input
for DESeq.Classification of miRNA and mRNA expression profile
All of the detectable miRNAs were applied to PCA [49]
and HCA [50] to determine the global effects of AA
treatment on miRNA expression. The analysis was done
within ArrayTrack™, an FDA-developed software pack-
age for managing, analyzing, and interpreting microarray
gene expression data [51]. The sequencing data were
normalized to let each sample have the same number
of reads of 1 million, log2 transformed, and scaled (let-
ting all the genes have the mean of 0 and standard de-
viation of 1 across the 8 samples) prior to analysis.
PCA were conducted using the autoscaled method. For
HCA, the distance matrix was calculated using the Euclid-
ean method and the dendrogram was linked with average
algorithm.Functional analysis of the DEMs
The functional relevance of the DEMs was analyzed
within IPA systems (http://www.ingenuity.com/), an on-
line functional analysis software that annotates the genes
in terms of biological functions. Also, we used IPA to
pull out cancer related miRNAs and cancer-related
miRNA targets from miRTarBase and link them to-
gether. Fisher’s exact test was used to evaluate the func-
tion changes. A function with a p-value < 0.05 was
considered as significantly affected by the AA treatment.Proteomic analysis of protein changes in rat kidneys
The proteomic analysis of the same set of rat kidneys for
miRNA/mRNA profiling was performed at Center for
Proteomics, National Center for Toxicological Research
(NCTR) by following a standard procedure as detailed
in a previous study [52]. Briefly, proteomes of rat
kidney were quantitatively analyzed using trypsin
catalyzed 16O/18O labeling in conjunction with two-
dimensional liquid chromatography separation and
tandem mass spectrometry (2DLC-MS/MS). More
than 9000 unique peptide sequences, were identified
and quantified. The false discovery rate (FDR) was es-
timated to be < 2% at the peptide level for these pep-
tide datasets as a result of a reversed protein sequence
database search. Evaluation of quantification errors
and statistic analysis was performed for the identifica-
tion of reliable protein expression changes as a result
of AA treatment. p < 0.05 to define differentially
expressed proteins.
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Additional file 1: Table S1. The differentially expressed microRNAs in
AA-treated rat kidney.
Additional file 2: Figure S1. TaqMan confirmation of 6 microRNA
expressions determined by NGS. Six microRNAs, which have low, middle,
or high expression levels, significant or non-significant expression
changes, and down or up change directions, were selected to do
TaqMan real-time PCR. Shown here are the fold changes detected by
two technologies.
Additional file 3: Figure S2. IPA analysis of differential mRNAs treated
with AA in rat kidney. (A) The canonical pathway of 4051 upregulated
genes. (B) The canonical pathway of 2743 downregulated genes.
Additional file 4: Figure S3. Correlation among miRNAs, mRNAs, and
proteins. We conducted genome-wide correlation analyses of expression
changes between mRNAs vs. protein, miRNA vs. mRNA, and miRNA vs.
protein in kidney in rats treated with AA. The Graphpad Prism 5.1 was
used for this analysis. We calculated the correlation coefficient R and P
value. P < 0.05 indicates significant difference.
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